1. Home
  2. GOSS vs GAIN Comparison

GOSS vs GAIN Comparison

Compare GOSS & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$2.32

Market Cap

615.7M

Sector

Health Care

ML Signal

HOLD

Logo Gladstone Investment Corporation Business Development Company

GAIN

Gladstone Investment Corporation Business Development Company

HOLD

Current Price

$13.98

Market Cap

556.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
GAIN
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
615.7M
556.7M
IPO Year
2019
2005

Fundamental Metrics

Financial Performance
Metric
GOSS
GAIN
Price
$2.32
$13.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$8.83
$14.75
AVG Volume (30 Days)
5.5M
196.5K
Earning Date
03-12-2026
02-03-2026
Dividend Yield
N/A
10.73%
EPS Growth
N/A
65.30
EPS
N/A
3.17
Revenue
$44,051,000.00
$101,433,000.00
Revenue This Year
N/A
$5.70
Revenue Next Year
$6.41
$6.41
P/E Ratio
N/A
$4.41
Revenue Growth
N/A
13.00
52 Week Low
$0.76
$11.42
52 Week High
$3.87
$15.34

Technical Indicators

Market Signals
Indicator
GOSS
GAIN
Relative Strength Index (RSI) 39.85 52.95
Support Level $2.24 $13.80
Resistance Level $2.41 $14.10
Average True Range (ATR) 0.22 0.23
MACD -0.00 0.01
Stochastic Oscillator 21.85 55.07

Price Performance

Historical Comparison
GOSS
GAIN

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About GAIN Gladstone Investment Corporation Business Development Company

Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.

Share on Social Networks: